Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 May 10:213:114685.
doi: 10.1016/j.jpba.2022.114685. Epub 2022 Feb 22.

Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application

Jennifer C Goodell  1 , Sara M Zimmerman  1 , Cody J Peer  1 , Varun Prabhu  2 , Tyler Yin  1 , William J Richardson  1 , Arya Azinfar  1 , John A Dunn  2 , Mark Mullin  2 , Brett J Theeler  3 , Mark Gilbert  4 , William D Figg  5
Affiliations
Clinical Trial

Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application

Jennifer C Goodell et al. J Pharm Biomed Anal. .

Abstract

ONC206 is an imipridone derivative that is being developed clinically as a single agent given orally in a first-in-human trial (NCT04541082). This ongoing clinical trial requires pharmacokinetic analysis of ONC206 to fully characterize its pharmacologic profile. There is currently no published bioanalytical method for ONC206 quantitation. To understand the clinical pharmacokinetics of ONC206, a sensitive yet simple uHPLC-MS/MS method for quantitation of ONC206 in human plasma was developed. Protein-precipitation allowed rapid and sensitive bioanalytical measurement of ONC206 in human plasma. A Phenomenex Kinetex C18 (50 ×2.1 mm, 1.3 µm, 100 Å) analytical column achieved symmetrical and sharp chromatography peaks of ONC206 and the internal standard, [2H]7-ONC206, which were detected using multiple reaction monitoring. The assay calibration range was 1-500 ng/mL and was best fit by a linear regression model (r2 > 0.99732 ± 0.0010). The method proved accurate (< ± 9% deviation), precise (<11%CV), selective and specific with no interference and low inter-lot matrix variability. ONC206 demonstrated excellent short-term, long-term, and multiple freeze-thaw cycle stability in solution and human plasma. This fully validated method was used to quantitate ONC206 plasma concentrations from patients enrolled in the aforementioned clinical trial at the NCI to demonstrate its clinical applicability.

Keywords: Clinical pharmacology; Mass spectrometry; ONC206; Ultra-HPLC.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Structures of ONC206 and the internal standard, ONC206-D7.
Figure 2.
Figure 2.
LC-MS/MS chromatograms of (A) a blank plasma extract, (B) internal standard only extract, and (C) the lower limit of quantification (LLOQ) with proposed fragmentation patterns.
Figure 3.
Figure 3.
Phase I clinical trial data. ONC206 Cycle 1 plasma concentration vs. time curve for individual patients dosed at 50 mg, 100 mg, and 150 mg.
See this image and copyright information in PMC

References

    1. Allen JE, Krigsfeld G, Mayes PA, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013;5(171): 171ra117. - PMC - PubMed
    1. Allen JE, Krigsfeld G, Patel L, et al. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015;14: 99. - PMC - PubMed
    1. Ishizawa J, Kojima K, Chachad D, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016;9(415): ra17. - PMC - PubMed
    1. Prabhu VV, Morrow S, Rahman Kawakibi A, et al. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. Neoplasia. 2020;22(12): 725–744. - PMC - PubMed
    1. Chi AS, Tarapore RS, Hall MD, et al. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol. 2019; 145(1): 97–105. - PMC - PubMed

Publication types

MeSH terms

Substances